Showing results (81-90 of 185) with videos related to
Sort By:
Pageof 19
Oncology|July 16, 2019
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.Drugs - Real World Outcomes|July 19, 2023
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective AnalysisHiroaki Kanzaki, Sadahisa Ogasawara, Tomomi Okubo, et al.Liver Cancer|October 1, 2020
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular CarcinomaSusumu Maruta, Sadahisa Ogasawara, Yoshihiko Ooka, et al.European Journal of Gastroenterology & Hepatology|April 14, 2020
Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Oncology|April 27, 2021
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting AnalysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 18, 2020
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|December 28, 2019
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edemaMasanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2023
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH StudyKazufumi Kobayashi, Sadahisa Ogasawara, Susumu Maruta, et al.Gastroenterology Report|May 24, 2021
Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinomaAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Liver Cancer|May 12, 2021
What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Pageof 19